Scotiabank analyst Sung Ji Nam maintains $Castle Biosciences (CSTL.US)$ with a buy rating, and adjusts the target price from $37 to $44.
According to TipRanks data, the analyst has a success rate of 49.0% and a total average return of -0.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Castle Biosciences (CSTL.US)$'s main analysts recently are as follows:
Castle Biosciences reported another robust quarter of financial performance, surpassing expectations and achieving its second successive quarter of GAAP profitability. The positive risk/reward profile of the company's stock is emphasized. There is a significant possibility that payment for the company's squamous cell carcinoma test could be extended past the fourth quarter, considering that the company has been receiving payments for over two and a half years and has been effective in producing further evidence and data that may justify ongoing Medicare reimbursement.
Castle Biosciences experienced a solid third quarter with revenues aligning with projections and a positive trend in operational expenditure leverage. The company saw overall volume growth, although dermatology volumes fell short of expectations due to seasonal factors, while TissueCypher continued to show impressive momentum.
While coverage decisions for the SCC test continue to be a point of concentration, it is observed that the company is augmenting volumes for other tests, including growth in IDgenetix and TissueCypher. The robust performance of these tests has played a significant role in the company's impressive quarterly results and the subsequent elevation in revenue projections.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
豐業銀行分析師Sung Ji Nam維持$Castle Biosciences (CSTL.US)$買入評級，並將目標價從37美元上調至44美元。
根據TipRanks數據顯示，該分析師近一年總勝率為49.0%，總平均回報率為-0.4%。
此外，綜合報道，$Castle Biosciences (CSTL.US)$近期主要分析師觀點如下：
castle biosciences報告了另一個強勁的財務季度表現，超出了預期，並實現了第二個連續季度的普通會計準則盈利。公司股票的正面風險/回報概況得到強調。公司鱗狀細胞癌檢測的支付可能會延長至第四季度之後，考慮到公司已經連續兩年半收到支付並一直有效地產生進一步的證據和數據，這可能會證明持續的醫療保險報銷。
castle biosciences經歷了一個穩固的第三季度，營收與預期一致，並且運營支出槓桿的趨勢積極。雖然由於季節因素，皮膚科學成交量未達預期，但公司總體成交量增長，而組織Cypher繼續表現出令人印象深刻的勢頭。
儘管鱗狀細胞癌檢測的覆蓋決策仍然是一個重點，但可以觀察到公司正在增加其他測試的成交量，包括IDgenetix和TissueCypher的增長。這些測試的強勁表現在公司令人印象深刻的季度業績和隨後的營收預期提升中發揮了重要作用。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
